Search - tctmd.com

Displaying 21 - 40 of 66

Sort: Relevancy | Date

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Shelley Wood

February 12, 2019

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

Advertisement

Recurrent Events Common Among Young Patients With CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

Alirocumab Price Slashed in Deal With Express Scripts

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content